.... Case Presentation: We describe the successful management of AHA secondary to multiple myeloma (MM) using emicizumab and targeted anti-myeloma therapy. The patient initially responded to bortezomib-dexamethasone but required teclistamab due to disease progression. Emicizumab maintained hemostatic...

...Meng-Jun Huang; Qing-Yi Zeng; Dan Chen; Chun-Xia Yang; Ying Yang; Man Zhou; Fen-Li Zhang; Qiu-Han Bian; Xiao-Yan Yang Introduction: Many reports indicate that the occurrence of multiple myeloma (MM) is closely related to inflammation and immunity. Although the survival rates have been gradually...

...Jiao Yang; Qingqing Hu; Jiaqing Lu; Jian Wang; Die Wu; Xiaoming Fei; Lixia Wang; Xianqiu Yu; Yu Tang Introduction: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe hypersensitivity reaction rarely documented in patients with multiple myeloma (MM). Methods: In our...

...Muhammad Faisal Aslam; Asfand Yar Cheema; Daniyal Shahid; Bibi Maryam; Debduti Mukhopadhyay; Mishaal Munir; Ali Najam; Hossam M. Ali; Qaiser Bashir; Faiz Anwer Background: Advances in novel therapies have improved outcomes for multiple myeloma (MM) patients and the use of allo-SCT has decreased...

.... 2024 Multiple myeloma Autologous stem cell transplant Newly diagnosed myeloma Triplet Meta-analysis High-dose therapy with melphalan followed by stem cell rescue at the upfront setting (upfront autologous stem cell transplant [ASCT]) has been the standard of care for newly diagnosed...

...Julie Barberio; Timothy L. Lash; Ajay K. Nooka; Ashley I. Naimi; Rachel E. Patzer; Christopher Kim Introduction: Most multiple myeloma (MM) patients experience cytopenias, likely driven by both disease and treatment-related factors. Immunomodulatory agents (IMiDs), which form the backbone of most...

... maturation antigen (BCMA), and both have recently gained approval by the US Food Drug Administration (FDA) for the treatment of relapsed and refractory multiple myeloma (RRMM). Summary: These therapies offer unprecedented responses in RRMM but present new challenges including cytokine release syndrome (CRS...

...Inbar Cohen; Iuliana Vaxman; Morie A. Gertz Background: High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) has become part of standard of care (SOC) in newly diagnosed multiple myeloma. In this review, we provide a historical perspective on ASCT since its introduction...

... remains controversial. This study aimed to investigate prognostic biomarkers for myeloma patients based on CPC presence. Methods: A comprehensive analysis was conducted on 309 consecutive patients diagnosed with either multiple myeloma or pPCL, utilizing peripheral blood smears stained with Wright-Giemsa...

...Jiaqi Shao; Enfan Zhang; Haoguang Chen; Zhen Cai; Mengmeng Dong Introduction: Multiple myeloma (MM) is a malignant proliferative disease of plasma cells. Abnormally cloned plasma cells secrete large amounts of monoclonal immunoglobulins in the bone marrow of MM patients. Serum urea nitrogen (sUN...

...Alexander D. Heini; Vera Ulrike Bacher; Dilara Akhoundova; Katja Seipel; Thomas Pabst Introduction: Bispecific antibodies have meaningfully expanded the therapeutic armamentarium in multiple myeloma. Talquetamab is a CD3+ T-cell-redirecting antibody targeting GPRC5D, which is expressed on multiple...

... allows the generation of multi-energy images with increased contrast and scanning speed or ultra-high spatial resolution (UHR) images with lower radiation doses, compared to the currently used energy integrating detector (EID) CT. Since the recognition of bone disease related to multiple myeloma...

...Salvatore Troisi; Valentina Giudice; Mario Troisi; Denise Morini; Andrea Crudele; Bianca Cuffa; Carmine Selleri; Bianca Serio Daratumumab, an anti-CD38 monoclonal antibody, is worldwide approved for treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM) patients and is available...

...Kazuhito Suzuki; Morio Matsumoto; Yasushi Hiramatsu; Naoki Takezako; Yotaro Tamai; Kenshi Suzuki Introduction: Elotuzumab and lenalidomide plus dexamethasone (ERd) is a standard salvage chemotherapy for multiple myeloma, and elotuzumab is commonly administered every 2 weeks after cycle 3...

...) and lymphoproliferative disorders, such as lymphomas. Instead, since the association with plasma cell diseases such as multiple myeloma and plasmacytoma is infrequent, there is a lack of literature. This manuscript aimed to revise the literature by describing a rare case of CD and plasmacytoma and attempting to explain...

... multiple myeloma (SMM, n = 2) and low-risk monoclonal gammopathy of undetermined significance (MGUS, n = 6). Six patients were on tyrosine kinase inhibitor treatment, 2 were in treatment-free remission. The only covariate associated with paraproteinemia was the presence of anemia, albeit with borderline...

... and prognostic value of multiple myeloma (MM). MYC gene-related abnormalities (MYC GAs) are one of the CAs, but their unfavorable impact has not been fully investigated in daily clinical practice. Methods: This study retrospectively analyzed the prognostic impact of MYC GAs on 81 patients through fluorescence...

...Josefin Hidman; Anders Larsson; Måns Thulin; Torbjörn Karlsson Introduction: In multiple myeloma, there is an increase in bone marrow microvascular density and enhanced renal lymphangiogenesis. Increased levels of the proangiogenic protein growth differentiation factor-15 (GDF15) have previously...

...Congyang Huang; Hanshan Liu; Li Jia; Min Lu; Suyun Hu Background/Aim: The impacts of health insurance status on survival outcomes in multiple myeloma (MM) have not been addressed in depth. The present study was conducted to identify definite relationships of cancer-specific survival (CSS...

...Hareth Nahi; Göran Walinder; Vishal Patel; Ying Qu; Aaron Levine; Istvan Majer; Lucie Kutikova; Eva Hellqvist Franck; Maria K. Svensson; Markus Hansson Introduction: Treatment-induced peripheral neuropathy (TIPN) is a complication of multiple myeloma (MM) treatment. Objective: This real-world...